Scholarlink

<p>An indoline derivative, 4-[(1-acetyl-2,3-dihydro-1H-indol-5-yl)sulfonylamino] benzamide (ADB), was synthesized and characterized using <sup>1</sup>H NMR, <sup>13</sup>C NMR, FT-IR, and LC-MS. Density functional theory (DFT) calculations revealed a small HOMO–LUMO energy gap, indicating potential biological activity. Mulliken charge, NPA, and NBO analyses confirmed the molecule’s polarity and stabilization through conjugation. Nonlinear optical (NLO) analysis showed that ADB exhibited superior NLO properties compared to urea. Molecular docking against 37 cancer-related proteins identified four high-affinity targets (PDB IDs: 3PXY, 1JXQ, 2IOK, 4AA4). Molecular dynamics (MD) simulations over 100 ns demonstrated that the 3PXY–ADB complex displayed the lowest RMSD variation and stable interactions. In silico ADMET profiling indicated favorable drug-likeness, pharmacokinetics, and an acceptable toxicity profile. Overall, these results highlight ADB as a novel indoline derivative with significant anticancer potential, meriting further in vitro and in vivo studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel indoline-based compound demonstrating antitumor potential through integrated computational analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月4日

查看全文
  • Dhinesh Kumar Manoharan,
  • Pradeep Ilayaperumal,
  • Sennappan Madhappan,
  • Venugopal Thiruvengadam,
  • Kavitha Selvaraj,
  • Gnanavel Sathasivam,
  • Sugan Sundaravadivelu,
  • Senthilkumar Chandrasekaran

摘要

An indoline derivative, 4-[(1-acetyl-2,3-dihydro-1H-indol-5-yl)sulfonylamino] benzamide (ADB), was synthesized and characterized using 1H NMR, 13C NMR, FT-IR, and LC-MS. Density functional theory (DFT) calculations revealed a small HOMO–LUMO energy gap, indicating potential biological activity. Mulliken charge, NPA, and NBO analyses confirmed the molecule’s polarity and stabilization through conjugation. Nonlinear optical (NLO) analysis showed that ADB exhibited superior NLO properties compared to urea. Molecular docking against 37 cancer-related proteins identified four high-affinity targets (PDB IDs: 3PXY, 1JXQ, 2IOK, 4AA4). Molecular dynamics (MD) simulations over 100 ns demonstrated that the 3PXY–ADB complex displayed the lowest RMSD variation and stable interactions. In silico ADMET profiling indicated favorable drug-likeness, pharmacokinetics, and an acceptable toxicity profile. Overall, these results highlight ADB as a novel indoline derivative with significant anticancer potential, meriting further in vitro and in vivo studies.